Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 5/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | SNCA | P37840 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ITGB2 | P05107 | 6/20 | 0.36 |
| ▸ | ICAM1 | P05362 | 6/20 | 0.36 |
| ▸ | ITGAL | P20701 | 6/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13902872 | 0.93 | ECE1 (0.38) | ECE1USP2MAPK1ALDH1A1SNCA | |
| SCHEMBL13902881 | 0.92 | MEN1 (0.37) | ECE1USP2MAPK1ALDH1A1SNCA | |
| SCHEMBL3939933 | 0.92 | SNCA (0.38) | ECE1USP2MAPK1SNCAITGB2 | |
| SCHEMBL13902874 | 0.92 | ECE1 (0.37) | ECE1USP2MAPK1ALDH1A1SNCA | |
| SCHEMBL13960316 | 0.92 | ECE1 (0.39) | ECE1USP2MAPK1ALDH1A1SNCA | |
| SCHEMBL13962345 | 0.92 | ECE1 (0.39) | ECE1USP2MAPK1ALDH1A1SNCA | |
| SCHEMBL13960314 | 0.92 | ECE1 (0.39) | ECE1USP2MAPK1ALDH1A1SNCA | |
| SCHEMBL13902875 | 0.92 | ECE1 (0.39) | ECE1USP2MAPK1ALDH1A1SNCA | |
| SCHEMBL13902870 | 0.91 | ECE1 (0.40) | ECE1USP2MAPK1ALDH1A1SNCA | |
| SCHEMBL13902864 | 0.91 | ECE1 (0.40) | ECE1USP2MAPK1ALDH1A1SNCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090075987-A1 | ALKYLACETYLENE SUBSTITUTED ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AG (DE) | 2009-03-19 | — | — | US | claimed |
| EP-2019102-A1 | Alkylacetylene substituted Acyltryptophanols | Bayer Schering Pharma AG (DE) | 2009-01-28 | — | — | EP | claimed |
| US-20090075987-A1 | ALKYLACETYLENE SUBSTITUTED ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AG (DE) | 2009-03-19 | — | — | US | disclosed |
| US-20090075987-A1 | ALKYLACETYLENE SUBSTITUTED ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AG (DE) | 2009-03-19 | — | — | US | disclosed |
| WO-2009013333-A1 | ALKYLACETYLENE SUBSTITUTED ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-29 | — | — | WO | disclosed |
| WO-2009013333-A1 | ALKYLACETYLENE SUBSTITUTED ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-29 | — | — | WO | disclosed |
| EP-2019102-A1 | Alkylacetylene substituted Acyltryptophanols | Bayer Schering Pharma AG (DE) | 2009-01-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075987-A1 | ALKYLACETYLENE SUBSTITUTED ACYLTRYPTOPHANOLS | FSHR, GNRHR, CYP19A1 | ECE1 1561/4885USP2 2589/4885MAPK1 3786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.